niclosamide has been researched along with Cancer of Esophagus in 3 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using a panel of esophageal cancer cell lines and normal cells, we show that niclosamide has anti-esophageal cancer activity and is likely to be less effective against normal esophageal epithelial and fibroblast cells." | 1.62 | Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer. ( Liu, H; Wei, W; Yao, Y; Yuan, J, 2021) |
| "Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells." | 1.56 | Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020) |
| "Niclosamide is an anthelmintic drug that also demonstrates great potential in fighting against cancers." | 1.42 | Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique. ( Wang, H; Wu, B; Ye, Y; Zhang, T; Zhang, X, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, MC | 1 |
| Chen, YK | 1 |
| Hsu, YJ | 1 |
| Lin, BR | 1 |
| Wei, W | 1 |
| Liu, H | 1 |
| Yuan, J | 1 |
| Yao, Y | 1 |
| Ye, Y | 1 |
| Zhang, X | 1 |
| Zhang, T | 1 |
| Wang, H | 1 |
| Wu, B | 1 |
3 other studies available for niclosamide and Cancer of Esophagus
| Article | Year |
|---|---|
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; | 2020 |
Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Topics: Animals; Anthelmintics; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neopla | 2021 |
Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Calorimetry, Differential Scanning; Cell Line, Tumor; | 2015 |